Monopar Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Monopar Therapeutics Inc. (Nasdaq: MNPR) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for life-threatening diseases. The company's pipeline is anchored by two primary pillars: ALXN1840, a late-stage, first-in-class tiomolybdate choline clinical program in-licensed from Alexion (AstraZeneca Rare Disease) for the treatment of Wilson disease, and a proprietary radiopharmaceutical platform centered around the uPAR-targeting monoclonal antibody MNPR-101. The radiopharmaceutical pipeline includes MNPR-101-Zr for precision imaging and dosimetry, and MNPR-101-Lu, a therapeutic radio-immunotherapy designed to treat uPAR-expressing advanced or metastatic solid tumors. Monopar operates with a lean corporate structure, utilizing strategic collaborations and in-licensing to advance its clinical candidates.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Building out the commercial infrastructure and strategy under the leadership of Susan Rodriguez (appointed Chief Commercial and Strategy Officer in March 2026) to prepare for the potential FDA approval and commercial launch of ALXN1840 for Wilson disease.
Expected impact: Enables rapid commercial uptake, broad patient access, and maximization of the therapy's market impact upon potential regulatory approval.
Actively enrolling and executing clinical trials in Australia for MNPR-101-Zr (Phase 1 imaging and dosimetry) and MNPR-101-Lu (Phase 1a therapeutic) targeting advanced solid tumors expressing uPAR.
Expected impact: Establishes a theranostic pipeline (paired imaging and therapy) for aggressive cancers with high unmet medical needs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Acquired exclusive global rights to develop and commercialize ALXN1840, a novel clinical-stage oral therapeutic for Wilson disease. This asset significantly accelerates Monopar's timeline to potential commercialization, as Phase 3 clinical trials have already been completed.
Terms: Monopar paid an upfront consideration of $4.0 million in cash and issued 9.9% of its outstanding common stock to Alexion. Alexion is also entitled to receive pre-determined regulatory and sales milestones, alongside tiered royalties on future net sales.
Secures a long-term, non-exclusive supply of the therapeutic radioisotope actinium-225 (Ac-225) to support Monopar's therapeutic radiopharmaceutical programs (such as MNPR-101-Ac). The amendment also transferred full ownership of certain jointly developed intellectual property rights for the MNPR-101 platform to Monopar.
Terms: Monopar acquired full ownership of the MNPR-101 radiopharmaceutical platform rights from NorthStar, with both companies sharing ownership of the patent application for using PCTA as a linker with Ac-225.